Rezultati
eNauka >
Rezultati >
MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
| Naziv: | MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab plus Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma | Autori  : | Zamagni, Elena; ...; Bila, Jelena S.   ; ...; (broj koautora 22) |
Godina: | 2022 | Publikacija: | Blood (64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Dec 10-13, 2022, New Orleans, LA) | ISSN: | 0006-4971 Blood Pretraži identifikator |
Izdavač: | [New York] : Elsevier | Tip rezultata: | Konferencijski rad | Kolacija: | vol. 140 br. Suppl 1 str. 7289-7291 | DOI: | 10.1182/blood-2022-159756 | WoS-ID: | 000893230300132 | URI: | https://enauka.gov.rs/handle/123456789/802479 | URL: | https://ashpublications.org/blood/article/140/Supplement%201/7289/487791/MajesTEC-4-EMN30-A-Phase-3-Trial-of-Teclistamab | Izvor metapodataka: | (Preuzeto iz Nasi u WoS) | M-kategorija: | Mp kategorija će biti prikazana naknadno. |
Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.